Placebo-Controlled Trial of Ketanserin in the Treatment of Intermittent Claudication

Publisher Website
Google Scholar
Abstract
The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change +12%, 95% CI -9; +33%) or total walking time (mean change -14%, 95% CI - 47%; + 19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.